# Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer

> **NCT04364672** · PHASE1 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 18F-labeled DPA-714 PET scan

## Key facts

- **NCT ID:** NCT04364672
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of recruitment and funding
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364672, "Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04364672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*